Trial Outcomes & Findings for Evaluating a Telehealth Treatment for Veterans With Hepatitis C and PTSD (NCT NCT00333710)

NCT ID: NCT00333710

Last Updated: 2014-12-15

Results Overview

This is a 62-item measure which assesses knowledge of the hepatitis C Virus. Range is 0 to 62. Higher scores reflect greater hepatitis C knowledge

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

53 participants

Primary outcome timeframe

pre-treatment, post-treatment

Results posted on

2014-12-15

Participant Flow

Participant milestones

Participant milestones
Measure
Individual Face-to-face Contact
Individual face-to-face contact treatment Individual psychotherapy: Individual face-to-face contact with educational and goal setting components
Individual Telephone Contact
Individual telephone contact treatment Telehealth Intervention: Individual telephone contact with educational and goal setting components
Control Condition/Treatment as Usual
Control condition/treatment as usual
Overall Study
STARTED
19
18
16
Overall Study
COMPLETED
8
14
15
Overall Study
NOT COMPLETED
11
4
1

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Evaluating a Telehealth Treatment for Veterans With Hepatitis C and PTSD

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Individual Face-to-face Contact
n=19 Participants
Individual face-to-face contact treatment Individual psychotherapy: Individual face-to-face contact with educational and goal setting components
Individual Telephone Contact
n=18 Participants
Individual telephone contact treatment Telehealth Intervention: Individual telephone contact with educational and goal setting components
Control Condition/Treatment as Usual
n=16 Participants
Control condition/treatment as usual. No active treatment
Total
n=53 Participants
Total of all reporting groups
Age, Continuous
54.37 years
STANDARD_DEVIATION 4.89 • n=5 Participants
52.28 years
STANDARD_DEVIATION 5.19 • n=7 Participants
55 years
STANDARD_DEVIATION 6.80 • n=5 Participants
53.85 years
STANDARD_DEVIATION 5.64 • n=4 Participants
Sex: Female, Male
Female
3 Participants
n=5 Participants
1 Participants
n=7 Participants
0 Participants
n=5 Participants
4 Participants
n=4 Participants
Sex: Female, Male
Male
16 Participants
n=5 Participants
17 Participants
n=7 Participants
16 Participants
n=5 Participants
49 Participants
n=4 Participants
Region of Enrollment
United States
19 participants
n=5 Participants
18 participants
n=7 Participants
16 participants
n=5 Participants
53 participants
n=4 Participants

PRIMARY outcome

Timeframe: pre-treatment, post-treatment

This is a 62-item measure which assesses knowledge of the hepatitis C Virus. Range is 0 to 62. Higher scores reflect greater hepatitis C knowledge

Outcome measures

Outcome measures
Measure
Individual Face-to-face Contact
n=8 Participants
Individual face-to-face contact treatment Individual psychotherapy: Individual face-to-face contact with educational and goal setting components
Individual Telephone Contact
n=14 Participants
Individual telephone contact treatment Telehealth Intervention: Individual telephone contact with educational and goal setting components
Control Condition/Treatment as Usual
n=15 Participants
Control condition/treatment as usual
Hepatitis C Virus Knowledge Questionnaire
Pre-Treatment
37.88 units on a scale
Standard Deviation 10.78
40.50 units on a scale
Standard Deviation 6.19
35.80 units on a scale
Standard Deviation 10.05
Hepatitis C Virus Knowledge Questionnaire
Post-Treatment
45.38 units on a scale
Standard Deviation 7.89
42.36 units on a scale
Standard Deviation 6.03
34.73 units on a scale
Standard Deviation 11.09

Adverse Events

Individual Face-to-face Contact

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Individual Telephone Contact

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Control Condition/Treatment as Usual

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Amy Silberbogen, Ph.D.

VA Boston Healthcare System

Phone: 857-364-4707

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place